Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a
                    <i>FLT3</i>
                    Mutation

M. Stone, Richard; J. Mandrekar, Sumithra; L. Sanford, Ben; Laumann, Kristina; Geyer, Susan; D. Bloomfield, Clara; Thiede, Christian; W. Prior, Thomas; Döhner, Konstanze; Marcucci, Guido; Lo-Coco, Francesco; B. Klisovic, Rebecca; Wei, Andrew; Sierra, Jorge; A. Sanz, Miguel; M. Brandwein, Joseph; de Witte, Theo; Niederwieser, Dietger; R. Appelbaum, Frederick; C. Medeiros, Bruno; S. Tallman, Martin; Krauter, Jürgen; F. Schlenk, Richard; Ganser, Arnold; Serve, Hubert; Ehninger, Gerhard; Amadori, Sergio; A. Larson, Richard; Döhner, Hartmut

doi:10.1056/nejmoa1614359

Public

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Shared by NobleBlocks on Jun 23, 2017 • 12:00 AM UTC

Authors:

R. Stone

S. Mandrekar

B. Sanford

Abstract

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolon...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!